Neuromuscular Blockade
4
Pipeline Programs
2
Companies
1
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
3
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
M&
U
SUGAMMADEXApproved
sugammadex
Unknown Companyinjection
Competitive Landscape
2 companies ranked by most advanced pipeline stage
M&
Merck & Co.RAHWAY, NJ
5 programs1
1
sugammadexPhase 41 trial
MK-8616Phase 21 trial
E-learning course in neuromuscular monitoringN/A1 trial
Measurements of the level of neuromuscular blockadeN/A1 trial
Neuromuscular Blocking AgentN/A1 trial
Active Trials
+2 more trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Merck & Co.sugammadex
Clinical Trials (1)
Total enrollment: 50 patients across 1 trials
Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency
Start: Aug 2016Est. completion: Feb 201850 patients
Phase 4Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space